Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-19
2011-07-19
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S235000
Reexamination Certificate
active
07981913
ABSTRACT:
There is provided a series of substituted isophthalates of formula (I)or a stereoisomer thereof; or a pharmaceutically acceptable salt thereof, wherein W, R3, R5and R6as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.
REFERENCES:
patent: WO 02/02512 (2002-01-01), None
patent: WO 02/02518 (2002-01-01), None
patent: WO 2004/043916 (2004-05-01), None
patent: WO 2005/016876 (2005-02-01), None
Cecil Textbook of Medicine, 20thedition (1996), vol. 2, pp. 2050-2057.
Cecil Textbook of Medicine, 20thedition (1996), vol. 2, pp. 1992-1996.
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrieved from the internet, URL <http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html>.
Coburn, C.A., et al., “Identification of a Small Molecule Nonpeptide Active Site β-Secretase Inhibitor That Displays a Nontraditional Binding Mode for Aspartyl Proteases”,J. Med. Chem.(2004) 47 (25): 6117-6119.
Hussain, I. et al., “Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase”,Mol. Cell. Neurosci, (1999) 14: 419-427.
Horn, R.K., et al., “Design and Synthesis of Hydroxyenthylene-Bses Peptidomimetic Inhibitors of Human β-Secretase”,J. Med. Chem. (2004) 47 (1): 158-164.
Lin, X. et al., “Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein”, Proceedings of the National Academy of Sciences of the USA, (2000) 97: 1456-1460.
Luo, Y., et al., “Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation”,Nature Neuroscience(2001) 4: 231-232.
Roberds, S.L. et al.,“BACE knockout mice are healthy despite lacking the primary βsecretase activity in brain: implications for Alzheimer's disease therapeutics”,Human Molecular Genetics(2001) 10: 1317-1324.
Seiffert, D.; et al., “Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors”,J. Biol. Chem. (2000) 275, 34086-34091.
Selkoe, D. J., “Alzheimer's Disease: Genes, Proteins, and Therapy”,Physiol. Rev. (2001) 81, 741-766.
Selkoe, D. J., “Biochemical Analyses of Alzheimer's Brain Lesions lead to the Identification of αβ and its Precursor”,Ann. Rev. Cell Biol. (1994) 10: 373-403.
Sinha, S., et al., “Purification and cloning of amyloid precursor protein β-secretase from human brain”,Nature(London) (1999) 402: 537-540.
Stachet, S.J., et al., “Structure-Based Design of Potent and Selective Cell-Permeable Inhibitors of Human β-secretase (BACE-1)”,J. of Med. Chem. (2004) 47 (26): 6447-6450.
Thal, D. R., et al., “Two types of Sporadic Cerebral Amyloid Angiopathy”,J. Neuropath. and Exper. Neurology(2002) 61: 282-293.
Vassar, R., et al., “β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE”,Science(1999) 286: 735-741.
Walsh, D. M., et al., “Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo”,Nature(2002) 416, 535-539.
Wolfe, M. S., “Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential”,J. Med. Chem. (2001) 44, 2039-2060.
Yan, R. et al., “Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity”,Nature(1999) 402: 533-537.
Boy Kenneth M.
Macor John E.
Shi Jianliang
Thompson, III Lorin A.
Anderson Rebecca L
Bristol--Myers Squibb Company
Levis John F.
LandOfFree
Isophthalates as beta-secretase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isophthalates as beta-secretase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isophthalates as beta-secretase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2640828